secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001437749-25-007019
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences amends bonus plan; ties CEO payout to FDA approval of simufilam
--------------------------------------------------------------------------------

- Amendments require Chairman/President/CEO bonus only if FDA approves simufilam, except in Merger Transaction.
- Compensation Committee set all previously unallocated cash bonuses to zero and rescinded plan on Feb 13, 2025.
- No cash bonuses have been paid to any participant under the CIB Plan through the filing date.
- Changes result from shareholder derivative lawsuit settlement approved by Delaware Court of Chancery on Jan 24, 2025.
- Market cap milestones up to $5B remain; bonuses deferred until Company has sufficient cash for 24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925007019/0001437749-25-007019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925007019/sava20250310_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-007019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer